SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 10891100.
  • 2
    Myers BD, Ross JC, Newton LD, Luetscher JA, Perlroth MG. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 600705.
  • 3
    Young BA, Burdmann EA, Johnson RJ et al. Cyclosporin A induced arteriolopathy in a rat model of chronic cyclosporine nephrotoxicity. Kidney Int 1995; 48: 431438.
  • 4
    Franceschini N, Alpers CE, Bennett WM, Andoh TF. Cyclosporine arteriolopathy: Effects of drug withdrawal. Am J Kid Dis 1998; 32: 247253.
  • 5
    Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 11411151.
  • 6
    Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 21472159.
  • 7
    Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in chronic cyclosporine nephropathy. Kidney Int 1997; 52: 660673.
  • 8
    Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 11741185.
  • 9
    Shihab FS. Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin Nephrol 1996; 16: 536547.
  • 10
    Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111119.
  • 11
    Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am J Physiol 2002; 283: F1167F1175.
  • 12
    Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scan J Immunol 1991; 33: 161173.
  • 13
    Badid C, Vincent M, McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 5161.
  • 14
    Hauser IA, Renders L, Radeke HH, Sterzel RB, Gopelt-Struebe M. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 5863.
  • 15
    Dubus I, Vendrely B, Christophe I et al. Mycophenolic acid antagonizes the activation of cultured mesangial cells. Kidney Int 2002; 62: 857867.
  • 16
    Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle proliferation in rat aortic allografts. Transplant Immunol 1995; 3: 342351.
  • 17
    Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460466.
  • 18
    Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 13631366.
  • 19
    Yang CW, Ahn HJ, Kim WY et al. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 2002; 62: 2030.
  • 20
    Yang CW, Ahn HJ, Kim WY et al. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003; 75: 309315.
  • 21
    Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 14071415.
  • 22
    Choi MJ, Eustache JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 10981114.
  • 23
    Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998; 9: 22722282.
  • 24
    Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 20552066.
  • 25
    Jones EA, Shoskes DA. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair. J Urol 2000; 163: 9991004.
  • 26
    Valentin JF, Bruijn JA, Paul LC. Donor treatment with mycophenolate mofetil. Protection against ischemia-reperfusion injury in the rat. Transplantation 2000; 69: 344350.
  • 27
    Fujihara CK, Malheiros DMAC, Zatz R, Noronha IL. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 15101519.
  • 28
    Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 ablation in rats. Kidney Int 1999; 55: 945955.
  • 29
    Fujihara CK, Noronha IL, Malheiros DMAC, Antunes GR, De Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283290.
  • 30
    Takeda A, Morozumi K, Yoshida A et al. Studies of cyclosporine-associated arteriolopathy in renal transplantation: Does the long-term outcome of renal allografts depend on chronic cyclosporine nephrotoxicity Transplant Proc 1994; 26: 925928.
  • 31
    Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 1993; 4: 214221.
  • 32
    Collins BS, Davis CL, Marsh CL, McVicar JP, Perkins JD, Alpers CE. Reversible cyclosporine arteriolopathy. Transplantation 1992; 54: 732734.
  • 33
    Tapia E, Franco M, Sanchez-Lozada LG et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003; 63: 9941002.
  • 34
    Senda M, Delustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995; 60: 11431148.
  • 35
    Fujihara CK, Malheiros DMAC, Noronha IL, De Nucci G, Zatz R. Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 2001; 37: 170175.
  • 36
    Lui SL, Chan LYY, Zhang XH et al. Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2001; 16: 15771582.
  • 37
    Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10: 15421549.
  • 38
    Young BA, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439448.
  • 39
    Cohn RG, Mirkovich A, Dunlap B et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411418.
  • 40
    Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology 1993; 26: 1120.
  • 41
    Heemann U, Azuma H, Hamar P, Schmid C, Tiney N, Philipp T. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant Immunol 1996; 4: 6467.
  • 42
    Blaheta RA, Leckel K, Wittig B et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant Immunol 1998; 6: 251259.
  • 43
    Noris M, Azzollini N, Pezzotta A et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 19371946.
  • 44
    Shehata M, Cope GH, Johnson TS, Raftery AL, El Nahas AM. Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 14871496.
  • 45
    Shihab FS. Renin-angiotensin system in chronic renal allograft dysfunction. Contrib Nephrol 2001; 135: 222234.
  • 46
    Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 11861196.
  • 47
    Rodriguez-Iturbe B, Pons H, Quiroz Y et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001; 59: 22222232.
  • 48
    Wu MS, Yang CW, Chang CT. Mycophenolic acid reduces renin-angiotensin-system activity in cultured mouse medullary thick ascending limb cells. Transpl Int 2002; 15: 655659.